Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04395391 · ClinicalTrials.gov registry record

Home Usability Study of the SARS-CoV-2 (COVID-19) Test

A clinical trial of COVID-19, sponsored by Exact Sciences Corporation.

Completed
Registry status
30
Enrollment target
1
Study location

NCT04395391: Completed study of COVID-19, sponsored by Exact Sciences Corporation.

NCT04395391 is a study of COVID-19 that has completed, run by Exact Sciences Corporation. The registered enrollment target is 30 participants, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04395391, a study of COVID-19, has completed, sponsored by Exact Sciences Corporation.

COMPLETED
Registry status
30 participants
Enrollment target
1
Study location

Study Summary

The primary objective is to determine the usability of the SARS-CoV-2 Specimen Collection Materials for at-home collection and mailing of sample to the testing laboratory.

Primary Outcome

The percent of samples from the fully enrolled cohort to return a valid SARS-CoV-2 test result (positive, not detected, or inconclusive)

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST SARS-CoV-2

Study Locations (1)

Wisconsin

  • Exact Sciences - Madison

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2020-05-18
Est. Completion 2020-06-16
Exact Sciences Corporation

30 total trials

What the finished NCT04395391 record still lists

NCT04395391 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).

The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which SARS-CoV-2 is the first listed.

NCT04395391 reports a single indexed study location in Wisconsin.

Frequently Asked Questions

What is clinical trial NCT04395391 about?

NCT04395391 is a clinical study titled "Home Usability Study of the SARS-CoV-2 (COVID-19) Test". The primary objective is to determine the usability of the SARS-CoV-2 Specimen Collection Materials for at-home collection and mailing of sample to the testing laboratory.

What is the current status of trial NCT04395391?

This trial is currently completed. The enrollment target is 30 participants. The study started on 2020-05-18. Estimated completion is 2020-06-16.

What conditions does trial NCT04395391 study?

This clinical trial studies the following conditions: COVID-19.

What interventions are being tested in trial NCT04395391?

The interventions under investigation include: SARS-CoV-2 (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT04395391?

This trial is sponsored by Exact Sciences Corporation, which has 30 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04395391 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04395391's enrollment target sits among peer trials

30 265th of 298 higher than 28 of 298 other COVID-19 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04395391, the US trial registry maintained by the National Library of Medicine. NCT04395391 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.